Interestingly, the fraction of the CSC-like CD44+/CD24-subpopulation differs among various prostate cancer cell lines and comprises only 0.04% of LNCaP cells [35] compared to ∼11% of PC-3 cells [36]. This evidence concerns the gene CD44 and prostate carcinoma.